A Randomized Controlled Trial of Sugammadex versus Neostigmine for Reversal of Rocuronium on Gastric Emptying in Adults Undergoing Elective Colorectal Surgery
Authors' conclusion
Sugammadex treatment was not associated with faster gastric emptying (primary end point).
Study context
- Population
- Adults undergoing elective colorectal surgeryITT analysis
- Participants
- 60 vs 60
- Comparison
- Sugammadex vs neostigmine-glycopyrrolate for reversal of rocuronium
- Sugammadexn = 60
- Neostigmine-glycopyrrolaten = 60reference
- Primary endpoint
- Gastric emptying (paracetamol absorption test; greater AUC = faster emptying)
Methodological detailspragmatic, single-centre, patient and assessor-blinded, Of 60 randomised to neostigmine-glycopyrrolate, 56 received it, 2 received sugammadex, 2 received both
- Pragmatic
- Single-centre
- Patient and assessor-blinded
- Of 60 randomised to neostigmine-glycopyrrolate, 56 received it, 2 received sugammadex, 2 received both
Primary result
As reported in the abstract
Gastric emptying (paracetamol AUC)
Sugammadex
1118
mean · SD 122
Neostigmine-glycopyrrolate
1130
SD 117
P = 0.58
Secondary outcomes
Hours
| Outcome | Sugammadex | Neostigmine-glycopyrrolate | Difference (hours) (95% CI) | P value | |
|---|---|---|---|---|---|
| Time to first bowel movementShorter with sugammadex | 44.3 (SD 33.8) | 61.0 (SD 43.0) | 16.7 (2.3–31.1) | P = 0.02 | |
| −2002040Difference, hours (linear scale) |
Minutes
| Outcome | Sugammadex | Neostigmine-glycopyrrolate | Difference (minutes) (95% CI) | P value | |
|---|---|---|---|---|---|
| Time to adequate reversal (TOFR ≥0.9)Shorter with sugammadex | 5.2 (SD 6.3) | 17.5 (SD 10.1) | 12.3 (9.2–15.4) | P < 0.001 | |
| −1001020Difference, minutes (linear scale) |
Days
| Outcome | Sugammadex | Neostigmine-glycopyrrolate | Difference (days) (95% CI) | P value | |
|---|---|---|---|---|---|
| Hospital LOS | 4.8 (SD 4.9) | 7.8 (SD 19.8) | 3 (- 2.2 to 8.3) | P = 0.27 | |
| −50510Difference, days (linear scale) |
PACU recovery time
difference (minutes) −6.9 (- 26.4 to 12.6) · P = 0.48
Safety
| Outcome | Sugammadex | Neostigmine-glycopyrrolate | OR (95% CI) | P value | |
|---|---|---|---|---|---|
| Gastrointestinal complications | 17% | 32% | 2.3 (0.9–6.2) | P = 0.09 | |
| 0.10.31310Odds ratio (log scale) |
Adverse events
- Similar between groups
Original publication
A Randomized Controlled Trial of Sugammadex versus Neostigmine for Reversal of Rocuronium on Gastric Emptying in Adults Undergoing Elective Colorectal Surgery. Anesth Analg. Published 6 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →